Market Overview:
The global macular degeneration treatment market reached a value of US$ 8.33 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 12.5 Billion by 2027 exhibiting a CAGR of 6.70% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Macular degeneration is a neurodegenerative ocular disorder that affects the eyes and causes blurred or loss of vision in the center of the visual field. It is characterized by blind spots in the field of vision, visual distortions and inability to see in low light conditions. Some of the commonly used therapeutic techniques for macular degeneration includes anti-angiogenic drugs, photodynamic laser therapies, contact lenses and transitional lenses. Laser therapy involves the insertion of specialized contact lenses into the affected are of the eye, which are sealed by lasers along with the blood vessels. Anti-angiogenic drugs are used for preventing blockages and leakages in the blood vessels. Timely treatment of macular degeneration treatment can aid in enhancing vision and minimizing the risks of developing chronic blindness.
www.imarcgroup.com
Note: Values and trends in the above chart consists of dummy data and are only shown here for representation purpose. Kindly contact us for the actual market size and trends.
Macular Degeneration Treatment Market Trends:
The increasing incidences of age-related macular degeneration and obesity among the masses is one of the key factors driving the market growth. The changing dietary patterns and the rising adoption of sedentary lifestyles is leading to the development of macular degeneration. Additionally, the increasing utilization of smartphones, laptops and television, which is leading to prolonged and excessive screen time is also impacting the occurrence of the disorder. Moreover, the development of retinal gene therapies that involves the injection of adeno-associated virus (AAV) into the body for preventing the development of abnormal blood vessels is providing a thrust to the market growth. In line with this, significant improvements in the healthcare infrastructure is positively impacting the market growth. Other factors, including extensive research and development (R&D) activities for the development of innovative and effective drugs, along with the implementation of various government initiatives for promoting public health, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global macular degeneration treatment market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, stage of disease, route of administration and end user.
Breakup by Type:
www.imarcgroup.com
Note: Values and trends in the above chart consists of dummy data and are only shown here for representation purpose. Kindly contact us for the actual market size and trends.
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
Breakup by Stage of Disease:
- Early Stage
- Intermediate Stage
- Late Stage
Breakup by Route of Administration:
- Intravenous Route
- Intravitreal Route
Breakup by End User:
- Hospitals
- Ambulatory Surgical Center
- Others
Breakup by Region:
To get more information on the regional analysis of this market, Request Sample
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Iveric Bio Inc., Novartis AG, Panoptica, Pfizer Inc., Phio Pharmaceuticals, Regeneron Pharmaceuticals Inc., Regenxbio Inc. and Santen Pharmaceutical Co. Ltd.
Report Coverage:
| Report Features |
Details |
|---|
| Base Year of the Analysis |
2021 |
| Historical Period |
2016-2021 |
| Forecast Period |
2022-2027 |
| Units |
US$ Billion |
| Segment Coverage |
Type, Stage of Disease, Route of Administration, End User, Region |
| Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
| Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
| Companies Covered |
Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Iveric Bio Inc., Novartis AG, Panoptica, Pfizer Inc., Phio Pharmaceuticals, Regeneron Pharmaceuticals Inc., Regenxbio Inc. and Santen Pharmaceutical Co. Ltd. |
| Customization Scope |
10% Free Customization |
| Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
| Post-Sale Analyst Support |
10-12 Weeks |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global macular degeneration treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global macular degeneration treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the stage of disease?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global macular degeneration treatment market and who are the key players?
- What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Macular Degeneration Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 Dry Age-related Macular Degeneration
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Wet Age-related Macular Degeneration
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by Stage of Disease
7.1 Early Stage
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Intermediate Stage
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Late Stage
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Route of Administration
8.1 Intravenous Route
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Intravitreal Route
8.2.1 Market Trends
8.2.2 Market Forecast
9 Market Breakup by End User
9.1 Hospitals
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Ambulatory Surgical Center
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Others
9.3.1 Market Trends
9.3.2 Market Forecast
10 Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2 Asia-Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3 Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4 Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Aerie Pharmaceuticals Inc.
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.2 Bausch Health Companies Inc.
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3 Bayer AG
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4 F. Hoffmann-La Roche Ltd
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 Financials
15.3.5 Iveric Bio Inc.
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 Financials
15.3.6 Novartis AG
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7 Panoptica
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.8 Pfizer Inc.
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 Phio Pharmaceuticals
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.10 Regeneron Pharmaceuticals Inc.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis
15.3.11 Regenxbio Inc.
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio
15.3.11.3 Financials
15.3.11.4 SWOT Analysis
15.3.12 Santen Pharmaceutical Co. Ltd.
15.3.12.1 Company Overview
15.3.12.2 Product Portfolio
15.3.12.3 Financials
15.3.12.4 SWOT Analysis
List of Figures
Figure 1: Global: Macular Degeneration Treatment Market: Major Drivers and Challenges
Figure 2: Global: Macular Degeneration Treatment Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Macular Degeneration Treatment Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 4: Global: Macular Degeneration Treatment Market: Breakup by Type (in %), 2021
Figure 5: Global: Macular Degeneration Treatment Market: Breakup by Stage of Disease (in %), 2021
Figure 6: Global: Macular Degeneration Treatment Market: Breakup by Route of Administration (in %), 2021
Figure 7: Global: Macular Degeneration Treatment Market: Breakup by End User (in %), 2021
Figure 8: Global: Macular Degeneration Treatment Market: Breakup by Region (in %), 2021
Figure 9: Global: Macular Degeneration Treatment (Dry Age-related Macular Degeneration) Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: Global: Macular Degeneration Treatment (Dry Age-related Macular Degeneration) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 11: Global: Macular Degeneration Treatment (Wet Age-related Macular Degeneration) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: Global: Macular Degeneration Treatment (Wet Age-related Macular Degeneration) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 13: Global: Macular Degeneration Treatment (Early Stage) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: Global: Macular Degeneration Treatment (Early Stage) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: Global: Macular Degeneration Treatment (Intermediate Stage) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: Global: Macular Degeneration Treatment (Intermediate Stage) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: Global: Macular Degeneration Treatment (Late Stage) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: Global: Macular Degeneration Treatment (Late Stage) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: Global: Macular Degeneration Treatment (Intravenous Route) Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: Global: Macular Degeneration Treatment (Intravenous Route) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 21: Global: Macular Degeneration Treatment (Intravitreal Route) Market: Sales Value (in Million US$), 2016 & 2021
Figure 22: Global: Macular Degeneration Treatment (Intravitreal Route) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: Global: Macular Degeneration Treatment (Hospitals) Market: Sales Value (in Million US$), 2016 & 2021
Figure 24: Global: Macular Degeneration Treatment (Hospitals) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: Global: Macular Degeneration Treatment (Ambulatory Surgical Center) Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: Global: Macular Degeneration Treatment (Ambulatory Surgical Center) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: Global: Macular Degeneration Treatment (Other End Users) Market: Sales Value (in Million US$), 2016 & 2021
Figure 28: Global: Macular Degeneration Treatment (Other End Users) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 29: North America: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 30: North America: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: United States: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: United States: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 33: Canada: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 34: Canada: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: Asia-Pacific: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 36: Asia-Pacific: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 37: China: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 38: China: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 39: Japan: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 40: Japan: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 41: India: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 42: India: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 43: South Korea: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 44: South Korea: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 45: Australia: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 46: Australia: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 47: Indonesia: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 48: Indonesia: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 49: Others: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 50: Others: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 51: Europe: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 52: Europe: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 53: Germany: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 54: Germany: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 55: France: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 56: France: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 57: United Kingdom: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 58: United Kingdom: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 59: Italy: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 60: Italy: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 61: Spain: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 62: Spain: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 63: Russia: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 64: Russia: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 65: Others: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 66: Others: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 67: Latin America: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 68: Latin America: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 69: Brazil: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 70: Brazil: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 71: Mexico: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 72: Mexico: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 73: Others: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 74: Others: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 75: Middle East and Africa: Macular Degeneration Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 76: Middle East and Africa: Macular Degeneration Treatment Market: Breakup by Country (in %), 2021
Figure 77: Middle East and Africa: Macular Degeneration Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 78: Global: Macular Degeneration Treatment Industry: SWOT Analysis
Figure 79: Global: Macular Degeneration Treatment Industry: Value Chain Analysis
Figure 80: Global: Macular Degeneration Treatment Industry: Porter's Five Forces Analysis
List of Tables
Table 1: Global: Macular Degeneration Treatment Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Macular Degeneration Treatment Market Forecast: Breakup by Type (in Million US$), 2022-2027
Table 3: Global: Macular Degeneration Treatment Market Forecast: Breakup by Stage of Disease (in Million US$), 2022-2027
Table 4: Global: Macular Degeneration Treatment Market Forecast: Breakup by Route of Administration (in Million US$), 2022-2027
Table 5: Global: Macular Degeneration Treatment Market Forecast: Breakup by End User (in Million US$), 2022-2027
Table 6: Global: Macular Degeneration Treatment Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 7: Global: Macular Degeneration Treatment Market: Competitive Structure
Table 8: Global: Macular Degeneration Treatment Market: Key Players